Treatment of Hepatic Tuberculoma

Standard Treatment Regimen

The American Thoracic Society recommends a standard 6-month anti-tuberculosis regimen consisting of 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 4 months of isoniazid and rifampicin, with careful monitoring for hepatotoxicity 1, 2
The intensive phase (2 months) should include isoniazid 5 mg/kg (maximum 300 mg) daily, rifampicin 10 mg/kg (maximum 600 mg) daily, pyrazinamide 25-35 mg/kg daily, and ethambutol 15 mg/kg daily 1, 2
The continuation phase (4 months) should include isoniazid and rifampicin at the same doses 1, 2

The Centers for Disease Control and Prevention recommends measuring baseline liver function tests (AST, ALT, bilirubin) before initiating therapy 4, 1, 2
The World Health Organization suggests screening for hepatitis B and C in high-risk patients (injection drug users, those from endemic regions, HIV-positive patients) 1, 2
The American Liver Foundation advises documenting any pre-existing liver disease 4, 1, 2

The European Respiratory Society recommends stopping all hepatotoxic drugs and waiting for liver function to normalize before reintroduction if hepatotoxicity develops and the patient is not acutely ill with non-infectious disease 4, 5
The Infectious Diseases Society of America suggests switching to non-hepatotoxic alternatives while awaiting normalization if the patient is acutely ill or has infectious tuberculosis (e.g., cavitary disease) 4, 5, 6

The American Thoracic Society recommends omitting pyrazinamide and using isoniazid, rifampicin, and ethambutol for 2 months, followed by 7 months of isoniazid and rifampicin (total 9 months) for patients with advanced liver disease or baseline ALT >3× upper limit of normal 1, 2
The Centers for Disease Control and Prevention suggests omitting isoniazid and pyrazinamide and using rifampicin, ethambutol, and a fluoroquinolone (with or without an injectable agent) for 12-18 months for patients who cannot tolerate isoniazid 1, 2

The World Health Organization advises against stopping treatment prematurely in asymptomatic patients with transaminase elevations <5× normal, as this risks treatment failure and drug resistance 6
The American Liver Foundation recommends never ignoring bilirubin elevation, as any rise in bilirubin mandates immediate cessation of hepatotoxic drugs, regardless of transaminase levels 4, 5, 6